Payment overview · 2025
General Payments
$1,898.91
109 reported records · 22 companies
Healthcare provider profile · identity verified
Lisa Klock, DO
Allopathic & Osteopathic Physicians|Family Medicine · DES MOINES, IA · NPI 1891707832
Verified facts
What the public records show
CMS Open Payments records show Lisa Klock, DO received $1,898.91 in general payments during 2025 across 109 reported records.
PFIZER INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $350.91 | 18.5% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $277.14 | 14.6% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $266.33 | 14.0% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $185.84 | 9.8% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $107.48 | 5.7% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $94.30 | 5.0% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $91.07 | 4.8% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.56 | 4.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.00 | 4.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $71.38 | 3.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.56 | 2.6% | 3 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $40.39 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.90 | 1.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $30.01 | 1.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.67 | 1.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.91 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.38 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.78 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.40 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.65 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.47 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.78 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,898.91 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $169.27 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $147.88 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.76 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $124.13 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $120.46 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $107.48 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $105.24 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $94.30 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $91.07 | 8 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $90.28 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.00 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.00 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $64.22 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.56 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $12.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 63 |
| Lisinopril | Lisinopril | 222 | 60 |
| Omeprazole | Omeprazole | 209 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 35 |
| Gabapentin | Gabapentin | 187 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 31 |
| Potassium Chloride | Potassium Chloride | 108 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 27 |
| Metformin Hcl | Metformin Hcl | 88 | 27 |
| Trazodone Hcl | Trazodone Hcl | 88 | 21 |
| Glimepiride | Glimepiride | 87 | 20 |
| Furosemide | Furosemide | 82 | 24 |
| Meloxicam | Meloxicam | 81 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 21 |
| Simvastatin | Simvastatin | 72 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 20 |
| Ibuprofen | Ibuprofen | 69 | 16 |
| Losartan Potassium | Losartan Potassium | 68 | 20 |
| Sertraline Hcl | Sertraline Hcl | 68 | 15 |
| Tramadol Hcl | Tramadol Hcl | 61 | 15 |
| Valsartan | Valsartan | 61 | 20 |
| Montelukast Sodium | Montelukast Sodium | 57 | 14 |
| Metformin Hcl Er | Metformin Hcl | 56 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Lorazepam | Lorazepam | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 15 |
| Ozempic | Semaglutide | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 18 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 12 |
| Jardiance | Empagliflozin | 41 | 12 |
| Naproxen | Naproxen | 39 | 15 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Famotidine | Famotidine | 32 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Prednisone | Prednisone | 23 | 19 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 18 |
| Baclofen | Baclofen | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,898.91 · 109 records | PFIZER INC. | ABRYSVO, AUSTEDO XR, CAPLYTA, CAPVAXIVE, COBENFY, COMIRNATY, Cologuard Collection Kit, Doc Band, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, SHINGRIX, Symbravo, TRINTELLIX, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, VYNDAMAX, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error